Vincristine sulfate

目录号:S1241 别名: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。

规格 价格 库存 购买数量  
RMB 582.05 现货
RMB 2229.59 现货
RMB 7118.45 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献14篇:

客户使用该产品的2个实验数据:

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。
靶点
Microtubules [1]
(Cell-free assay)
32 μM
体外研究

Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用,Ki为85 nM。[1]在低浓度时,Vincristine抑制纺锤体,使染色体分离失败,进而导致中期停滞,并抑制有丝分裂。在较高浓度时,Vincristine可能干扰且诱导全部微管解聚。[2] Vincristine 诱导肿瘤细胞凋亡,且抑制SH-SY5Y细胞增殖,IC50为0.1 µM。Vincristine诱导有丝分裂停滞,促进caspase-3和-9及cyclin B的表达,但降低cyclin D的表达。[3] Vincristine通过干扰微管功能而诱导神经毒性形成,这会导致轴突运输堵塞,从而导致轴突变性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NYnldpRuS2WubDDWbYFjcWyrdImgRZN{[Xl? MlHPNE0xNjVizszN NIrpTJAzPCCq MWTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MXuyOVY3Ozd4OR?=
HepG2-HBV1.1 NVrySYQ1SXCxcITvd4l{KEG|c3H5 MnPDNE0xNjVizszN MUSyOEBp M1K2VYlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= MoOzNlU3PjN5Nkm=
HepG2.2.15 M4S0TGZ2dmO2aX;uJGF{e2G7 NF34cFMxNjFizszN MkHJNlQhcA>? Mk[3dJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u MXOyOVY3Ozd4OR?=
HepG2-HBV1.1 MnPMSpVv[3Srb36gRZN{[Xl? MViwMlEh|ryP MXqyOEBp MlXDdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u NU\zTWxZOjV4NkO3Olk>
HepG2-HBV1.1 NITlcotHfW6ldHnvckBCe3OjeR?= MX[wMlEh|ryP NETPcpI1QCCq NWD1cnZveHKxbX;0[ZMh[2WubDDlfINz\XSrb36gc4YhcGWyYYTpeIl{KEJidnnyeZMhdnWlbHXvZ4Fxe2mmczDpcpN1\WGmIH;mJIhmeGG2aYTpd{BDKH[rcoXzJGRidmVicHHyeIlkdGW| NYC3XmxNOjV4NkO3Olk>
HepG2-HBV1.1 MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DvN|AvOSEQvF2= NUfC[HV[OS13IHS= NUTWUJNEcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=> MoXnNlU3PjN5Nkm=
HepG2-HBV1.1 NFfsSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWKySHA1OC5zIN88US=> MYexMVUh\A>? M1PrfIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= MYqyOVY3Ozd4OR?=
HepG2-HBV1.1 M{fadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf3XXJuOC5zIN88US=> Mo\jNVIuPzJiaB?= NVvNTlVicW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm NY\UTYZGOjV4NkO3Olk>
HepG2-HBV1.1 NVXa[IVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKwMlEh|ryP NHvyXmUyOi15MjDo NV;YNZYycW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm MlfvNlU3PjN5Nkm=
Raji NYLLcW85TnWwY4Tpc44hSXO|YYm= NXTINmc5OC53wrFOwG0> M1HqOlczKGh? Mlv0ZYJwdGm|aHXzJIF2fG:yaHHnfeKh NHXVSZMzPTR2NkO3Oy=>
SK-MEL-28  NEPRU3dHfW6ldHnvckBCe3OjeR?= NFzjOo0{OCCwTR?= M2HHe|YhcA>? NXPLcY1JcW6mdXPld{BIOuLCk12gZ4VtdC2leXPs[UBienKnc4S= MYCyOVMyOzBzMB?=
H157 M2rTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3SzWWlEPTB;MT6wN{DDuSByLkC0JI1qfTKP M3nN[lI2OjV5OUGx
Jurkat M4C4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml34NU0{KG6P NUnsbodQPDkEoHi= NGLwXZBFVVOR NWXXTZJn\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? M2frT|I2OTV4MUS2
CEM M1nrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXexMVMhdk1? NX:4TXlFPDkEoHi= NIDz[XhFVVOR MY\k[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 NFPwfGMzPTF3NkG0Oi=>
P12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW2NU0{KG6P MYm0POKhcA>? MYTEUXNQ NWfNTGkz\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? M1HCc|I2OTV4MUS2
KB NWTSfIVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj2fI9KSzVyPUCuNFA1QSEEsTCwMlAxODFizszN MYCyOVA2QDV{Nh?=
KBv200 (ABCB1) NWK1PY9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTy[WRsUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=> NHrwW5AzPTB3OEWyOi=>
SUDHL6  NHqxV|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTWWmhVOeLCid88US=> MYC0PE84OiCq MofibY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MnSwNlQ6PjF4MES=
SUDHL6  NUHNd5hFTnWwY4Tpc44hSXO|YYm= NFHUXW0y6oDLzszN MUG3NkBp M37t[olv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF? Ml\FNlQ6PjF4MES=
HCT-116 M4rQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPIdG9pT0l3ME21JI5O M3jZblI1QTJ5OEW3
SKNBe2C NGq3PJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17NV2lEPTB;M{KuPOKyPC5yIH7N NFrxZ2ozPDl{MUmyNC=>
IGNR91 NIDxU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDuTWM2OD1{ND6zxtEyNjdibl2= NGjpcJIzPDl{MUmyNC=>
SKNAS NED2[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwNdMxNE4zKG6P MkXlNlQ6OjF7MkC=
LAN1 NWTxc3RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTwTWM2OD1{LkRCtVAvOiCwTR?= MnLCNlQ6OjF7MkC=
SHSY5Y MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzMd4pKSzVyPUiuNuKyOC54IH7N M1[2flI1QTJzOUKw
A549-WT NV6wRWlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\FSVY{UUN3ME2xPU41OzdiwsGgNE42QTRiIH7N NEHGOGUzPDh3OEiyOy=>
A549-R M1XrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1? MXGyOFg2QDh{Nx?=
MCF-7-WT NEH1OYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnITWM2OD1zNz63OVIhyrFiMD6yNVghKG6P M1vMNFI1QDV6OEK3
MCF-7-R NFXKTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTBTWM2OD13LkWzPUDDuSByLkG0OEAhdk1? NILHV|IzPDh3OEiyOy=>
A549-R NWnQTm1MS3m2b4TvfIlkcXS7IFHzd4F6 NIq2bVJKSzVyPUGyMlE4QCEEsTCwMlM{OyCwTR?= MXOyOFg2QDh{Nx?=
MCF-7-R Mn7FR5l1d3SxeHnjbZR6KEG|c3H5 M2TtPGlEPTB;NT61N|khyrFiMD6xOFQhdk1? NFnKXVQzPDh3OEiyOy=>
SW620 NVLB[I5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLCTWM2OD15LkiwJOKyKDBwMEigcm0> M4XHSVI1PzJ4N{O5
SW620/AD300 NH;wb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfLTWM2OD17MEmuOlAhyrFiOD65NUBvVQ>? NIrMUlUzPDd{NkezPS=>
HEK293/pcDNA3.1 NEHBWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPWbGxKSzVyPUGuOFUhyrFiMD6yNEBvVQ>? MVOyOFczPjd|OR?=
HEK293/ABCC1 M3PxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF7LkK5JOKyKDJwMEigcm0> M{PJ[lI1PzJ4N{O5
TCC NXvvbWx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHHNlQhcA>? M2C3N2lEPTB;N{Cgcm0> M2j3TVI1PzF4OUS0
TCC NWO3UpJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLKOoo1QCCq NGm1NJFKSzVyPUWwJI5O NIjiV28zPDdzNkm0OC=>
HepG2/ADM MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fZ[mlEPTB;Mj63PFY{yrFyLkKzO|Eh|ryP NHPhcIYzPDdyNEW1Oi=>
HepG2 NVzCO49wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7RTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1? MXuyOFcxPDV3Nh?=
MCF-7/ADR MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jiRmlEPTB;ND60PFI3yrFyLkKwO|Ah|ryP NUjQTZlpOjR5MES1OVY>
MCF-7 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq5UpgyUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= NEjFS3QzPDdyNEW1Oi=>
A-172  M3fXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHJb3kxNjIEoN88US=> NXLI[YxJOjRxN{KgbC=> NHPyfpRqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 NWfmb2R4OjR3M{CyN|U>
U-251MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfxZ5ZKOC5zwrFOwG0> MVeyOE84OiCq MkjKbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NISyfFYzPDV|MEKzOS=>
DLD-1 MnfYSpVv[3Srb36gRZN{[Xl? M3XqeVExOCCwTR?= NHHFTJQ1QCCq MkHudJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh M{jMWVI1PDB|NEWz
CCD18Co NYnKOJBMTnWwY4Tpc44hSXO|YYm= NYnLbI1kOTByIH7N M1iyOVQ5KGh? MoixdJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh M33qUVI1PDB|NEWz
DLD-1 M3;TU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmwMVExODBibl2= NYq1Wpl4PDhiaB?= NX32WGJNcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NXf1OYd1OjR2MEO0OVM>
CCD18Co NXXUOIVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVWwMVExODBibl2= MlLDOFghcA>? MoizbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NFe2WWEzPDRyM{S1Ny=>
HepG2 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG4WVhSOjRiaB?= NWjGVlY{UUN3ME21Nk426oDLzszN M4H3[VI1OzRzNki4
HEK293/pcDNA3.1 NY\RWGdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMEC0xtExNjByMEOg{txO MmjGNlQzQDR5OEO=
HEK293/MRP1 NEXJfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;nR2FKSzVyPUCuNFU2yrFyLkCxNlAh|ryP M13nSlI1Ojh2N{iz
Ramos MYTBdI9xfG:|aYOgRZN{[Xl? NX7xPJJWOuLCid88US=> MojPOFghcA>? MoO0bY5lfWOnczCzOE43LcLzMT65NkUh[XCxcITvd4l{ MYGyOFI2PjR7MR?=
NCI-H1299/pcDNA3 M2O1PGNmdGxiVnnhZoltcXS7IFHzd4F6 MU[wMVIxKG6P NXPoOYJSQTZiaB?= NULwepRlcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NEO0NW4zPDF5N{CxNi=>
H1299/ICAM-3 M{KwR2NmdGxiVnnhZoltcXS7IFHzd4F6 NESxOmkxNTJyIH7N M{nxelk3KGh? NUfMUJp2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mn7WNlQyPzdyMUK=
NCI-H1299/pcDNA3 NFvJTJVHfW6ldHnvckBCe3OjeR?= M{\uZ|EwPS9zMD:yNOKhdk1? NFe1[Hg6PiCq M2D0N4lv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA> NWjNR3lpOjRzN{ewNVI>
H1299/ICAM-3 NXP6TWk2TnWwY4Tpc44hSXO|YYm= M4\DWFEwPS9zMD:yNOKhdk1? MW[5OkBp M{HnRYlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA> M2nWblI1OTd5MEGy
W1 NXzuO5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMECzNkDPxE1? M1HVT|I1OTRyMUe2
W1VR MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDjOZpKSzVyPUCuNFU3KM7:TR?= NXn2OIFpOjRzNECxO|Y>
K562 NFjNZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrPTWM2OD1yLkCzNkDDuSByLkCwNUAh|ryP MWGyOFE{PTl|Nx?=
K562/ADR MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLhWYpKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?= NYDtZmdrOjRzM{W5N|c>
K562 MkPuRZBweHSxc3nzJGF{e2G7 M4XYTVAvOyEQvF2= M1\YcVI1KGh? M2jKS4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? M2LmWFI1OTN3OUO3
K562/ADR MUjBdI9xfG:|aYOgRZN{[Xl? NILV[5U{KM7:TR?= NVvWPI41OjRiaB?= M1n3XYlv\HWlZYOgZZBweHSxc3nz MV6yOFE{PTl|Nx?=
A549 NInHcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[yTWM2OD1yLkGwJOKyKDBwMEOg{txO M4D3O|I{QTdzMEe1
K562 NELZOWtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXSzMlc26oDVNkFCpI5O MX23NuKhcMLi NVzXTms4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MV6yN|g4PzJ{Mx?=
lucena M4noXWNmdGxiVnnhZoltcXS7IFHzd4F6 M3rKNlMvPzYkgKO2NOKhdk1? M2nzW|czyqCqwrC= MmnJco8h\W[oZXP0 NXvLbWI4OjN6N{eyNlM>
FEPS M4Hld2NmdGxiVnnhZoltcXS7IFHzd4F6 NWP5SmIxOy55NfMAl|YxyqCwTR?= NGjnT3M4OsLiaNMg NWfnZ4JNdm9iZX\m[YN1 NGLxOJUzOzh5N{KyNy=>
A2780 NVLLUGZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\3TWM2OD1|LkWgcW0> MVOyN|gzQTJyMx?=
ACHN M3OwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j0WGlEPTB:MD6xJI1O NX\wcWxLOjN6MkmyNFM>
U-937 M3[xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjVSmFKSzVyPEO0JI5O M{HjcVI{QDJ7MkCz
Jurkat NWnnd3NVSXCxcITvd4l{KEG|c3H5 M{iyW|XDqM7:Zz;tcOKh MYSyOEBp M3\Cc4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MUiyN|gyODRyOR?=
Jurkat M4j3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;TT40yPcLizsznM41tyqB? MnKzNlQhcA>? NWr0[HN1[XK{ZYP0JGp2emujdDDj[YxteyCrbjDHNk9OKHCqYYPl NYC4SIw2OjN6MUC0NFk>
Hep-2 NUHaNZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn70TWM2OD1yLkC0xtExNjBzIN88US=> MnHuNlM4QDB2MkS=
Hep-2/v M4LBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvtVVdKSzVyPUGuPOKyOC5{MDFOwG0> MmDkNlM4QDB2MkS=
SGC-7901 NXzy[nh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[2eFAuOTBizsznM41t M4rFd|I1NzR6L{eyJIg> NYf6[2ZRcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MnLLNlM4PDN3N{K=
SGC-7901/VCR MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorlNE0yOCEQvHevcYw> MWGyOE81QC95MjDo MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NHLVZXYzOzd2M{W3Ni=>
SGC-7901 MVPBdI9xfG:|aYOgRZN{[Xl? NH:0O3RqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 M3\WOFI{PzR|NUey
SGC-7901/VCR NXziPGdiSXCxcITvd4l{KEG|c3H5 MWDpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 M1LEbFI{PzR|NUey
KB-3-1 M{XJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwNk[gxtEhOC5zNkKg{txO NF\afIUzOzZ5M{S0OS=>
KB-C2 NWDsXJI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXLdpVyUUN3ME2yNFIvPTZiwsGgOFIvPDhzIN88US=> MkHtNlM3PzN2NEW=
KB-3-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPvTWM2OD1zLkK2JOKyKDBwMEK3JO69VQ>? M{n4T|I{Pjd|NES1
KB-V1 NV:0bmd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJyOD64OUDDuSB{MD60JO69VQ>? Mnn5NlM3PzN2NEW=
HEK293/pcDNA3.1 M3zxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXOTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>? NWjOOodwOjN4N{O0OFU>
HEK293/ABCB1 M1:4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvoTWM2OD1|NUGyMlghyrFiM{e4MlM6OSEQvF2= M2KwOVI{Pjd|NES1
A549/EGFP  NHXwTnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjsfWJ6OC5yMT2xNFAxKM7:TR?= M{DoU2lEPTB;OE[uO{DDuSB{OT6xJO69VQ>? NEXUOJQzOzZ|NEK4Ni=>
A549/Slug MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\zXlAvODFvMUCwNEDPxE1? MmrGTWM2OD17LkegxtEhOy5zIN88US=> MYqyN|Y{PDJ6Mh?=
JFCR39  MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxJOK2VQ>? M4mzTlI1KGh? M32ySmROW09? MnHhcYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG|ZTDj[Yxtew>? MknqNlM2QTh{N{[=
A549 NHGzWXdHfW6ldHnvckBCe3OjeR?= M{CxOlExOCCwTR?= NHXUUlAyPiCq NFr1bGtFVVOR NIjVdY9t\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW| NYq3d3FXOjN3OUiyO|Y>
SGC7901 NUTBfmhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG5b|FKSzVyPUGuNlbjiIoEsfMAjVAvOTFizsznM41t MYKyN|U3PDR6Mh?=
SGC7901/LV-NC NYi3WGxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW2TWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=> NEH3WWgzOzV4NES4Ni=>
SGC7901/LV-SGO1 NIPUVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fLdWlEPTB;ND6zOwKBkcLz4pEJNE4{PyEQvHevcYw> NXHEOpFTOjN3NkS0PFI>
SGC7901/VCR M2jVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy2T5FKSzV|PUKwMlU{6oDLwsJihKkyNjl4IN88[{9udA>? M3vMdlI{PTZ2NEiy
SGC7901/VCR-NC NWLjV4NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF7Lki25qCKyrIkgJmyMlAyKM7:Zz;tcC=> MX:yN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 M4nLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfMUVNKSzVyPU[uNVjjiIoEsfMAjVEvODNizsznM41t M{DWdVI{PTZ2NEiy
SGC7901/ADR NGrTO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3iyc2lEPTB;Nz64OgKBkcLz4pEJNE43PCEQvHevcYw> NUPDW4lCOjN3NkS0PFI>
SGC7901/ADR-NC MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRThwOURihKnDueLCiUCuOlgh|rypL33s NWDVR5B2OjN3NkS0PFI>
SGC7901/ADR-si-SGO1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS1[|A{UUN3ME2zMlQ36oDLwsJihKkxNjJ7IN88[{9udA>? Ml7xNlM2PjR2OEK=
SH-SY5Y  MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfJb|R7OC5yMEGtNVAh|ryP NVrqUI13OjRiaB?= MoXnTWM2OD1yLkGxN:KyOC5yMUKg{txO NGn5VnMzOzF{OUC2OS=>
SH-SY5Y  NE\ST4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnniNE4xODFvMUCg{txO M336RlQ5KGh? NHTmRmdKSzVyPUCuNFc5yrFyLkCwPUDPxE1? NEjoZ2EzOzF{OUC2OS=>
SH-SY5Y  NUjGUVlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHNVnBCOC5yMEGtNVAh|ryP NIn6W3Q4OiCq M{XwW2lEPTB;MD6wOVHDuTBwMEC4JO69VQ>? Mn3BNlMyOjlyNkW=
SH-SY5Y NX7jTppiSXCxcITvd4l{KEG|c3H5 NGX2NmoxNjFizszN NIfFcGcxNTJ2IHi= M2[4PIlv\HWlZYOgZZBweHSxc3nzJI9nKFOKLWPZOXkh[2WubIOg[o9tdG:5aX7nJINmdGxiY4njcIUh[XK{ZYP0JIF1KHSqZTDHNk9OKHCqYYPl NELvS24zOzF{OUC2OS=>
SH-SY5Y NF24[oZCeG:ydH;zbZMhSXO|YYm= MnfXNE4yKM7:TR?= M2nIWFAuOjRiaB?= MoHubY5lfWOnczDtbZRwfGmlIHHydoV{fMLi NGGzNpczOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

体内研究 Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠,平均生长延迟120天和52天以上,且再植指数分别为0.06%和5%。[5] Vincristine 处理小鼠,通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量,降低近75%。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
+ 展开
  • Cell lines: B16 黑色素瘤细胞
  • Concentrations: 10 nM
  • Incubation Time: 3 天
  • Method: 细胞按5 × 104 cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上,在37°C下 含5% CO2 和95% 空气 的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基,继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后,每天使用库氏计数器完成细胞计数
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带人类横纹肌肉瘤移植瘤Rh12的鼠
  • Formulation: 水溶液
  • Dosages: 3 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 923.04
化学式

C46H58N4O14S

CAS号 2068-78-2
稳定性 powder
in solvent
别名 Leurocristine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami March 2019 Phase 1
NCT03710772 Not yet recruiting CD20 Positive|Mantle Cell Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) January 31 2019 Phase 2
NCT03613428 Not yet recruiting Acute T Cell Leukemia Sichuan University December 1 2018 Phase 1|Phase 2
NCT03742258 Not yet recruiting Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma Not Otherwise Specified|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Northwestern University|National Cancer Institute (NCI) December 29 2018 Phase 1
NCT03704714 Not yet recruiting Aggressive Non-Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|CD20 Positive|Diffuse Large B-Cell Lymphoma Unclassifiable|Intravascular Large B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Northwestern University|Bristol-Myers Squibb (BMS)|National Cancer Institute (NCI) November 8 2018 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • 回答:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Vincristine sulfate | Vincristine sulfate供应商 | 采购Vincristine sulfate | Vincristine sulfate价格 | Vincristine sulfate生产 | 订购Vincristine sulfate | Vincristine sulfate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID